Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)

被引：0
|
作者：
Wang, M.
Bensinger, W.
Martin, T.
Alsina, M.
Siegel, D. S. D.
Gabrail, N. Y.
Hari, P.
Singhal, S.
Vescio, R. A.
Assouline, S. E.
Kunkel, L. A.
Vallone, M.
Wong, A.
Niesvizky, R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] John Theurer Canc Ctr, Hackensack, NJ USA
[6] Gabrail Canc Ctr, Canton, OH USA
[7] Med Coll Wisconsin, Miwaukee, WI USA
[8] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[10] McGill Univ, Jewish Gen Hosp, Clin Res Unit, Segal Canc Ctr,Lady Davis Inst, Montreal, PQ H3T 1E2, Canada
[11] ACT Biotech Inc, San Francisco, CA USA
[12] Onyx Pharmaceut, San Francisco, CA USA
[13] Onyx Pharmaceut, Emeryville, CA USA
[14] Cornell Univ, New York Presbyterian Hosp, Ctr Excellence Lymphoma & Myeloma, Weill Med Coll, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8025
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
    San-Miguel, Jesus F.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Bortezomib, Lenalidomide and Low-dose Dexamethasone (VRD) Versus Lenalidomide and Low-dose Dexamethasone (Ld) for Newly-diagnosed Multiple Myeloma- A Randomized Phase III Study-Interim Results
    Mookerjee, Anjali
    Gupta, Ritu
    Jasrotia, Shivali
    Sahoo, Ranjit
    Kumar, Rakesh
    Thulkar, Sanjay
    Sharma, Om Dutt
    Kumar, Lalit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01) : E5 - E6
  • [43] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
    Jagannath, Sundar
    Hofmeister, Craig C.
    Baz, Rachid C.
    Siegel, David Samuel DiCapua
    Vij, Ravi
    Chen, Christine
    Lonial, Sagar
    Anderson, Kenneth Carl
    Chen, Min
    Zaki, Mohamed H.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Khouri, Jack
    Faiman, Beth M.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Khan, Shahper N.
    Wei, Wei
    Valent, Jason
    Dean, Robert
    Samaras, Christy
    Jha, Babal K.
    Lazarus, Hillard
    Campagnaro, Erica L.
    Malek, Ehsan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Sobecks, Ronald
    Saunthararajah, Yogen
    Chew, Yap
    Orloff, Mohammed
    Reu, Frederic J.
    SEMINARS IN HEMATOLOGY, 2021, 58 (01) : 45 - 55
  • [45] A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)
    Berenson, James R.
    Yellin, Ori
    Cartmell, Alan D.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Nassir, Youram
    Vescio, Robert
    Swift, Regina A.
    BLOOD, 2010, 116 (21) : 1254 - 1255
  • [46] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [47] PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis
    Siegel, D. S. D.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Kukreti, V.
    Bahlis, N. J.
    Alsina, M.
    Somlo, G.
    Buadi, F.
    Reu, F. J.
    Song, K. W.
    Kunkel, L. A.
    Wong, A.
    Vallone, M.
    Orlowski, R. Z.
    Stewart, A. K.
    Singhal, S.
    Jagannath, S.
    Jakubowiak, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] PHASE (PH) I/II STUDY OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM): UPDATED PH II RESULTS AND PH I/II LONG TERM SAFETY
    Facon, T.
    Richardson, P.
    Jagannath, S.
    Moreau, P.
    Jakubowiak, A.
    Raab, M.
    Vij, R.
    White, D.
    Reece, D.
    Benboubker, L.
    Zonder, J.
    Deng, W.
    Bleickardt, E.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2013, 98 : 319 - 319
  • [49] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
    Stewart, A. K.
    Rajkumar, S. V.
    Dimopoulos, M. A.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Jakubowiak, A. J.
    San-Miguel, J. F.
    Zojwalla, N.
    Moreau, P.
    Palumbo, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
  • [50] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
    Dimopoulos, Meletios
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ardizzoia, Antonio
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Li, Yan
    Bacon, Pamela
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
12345